KR102702675B1 - 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도 - Google Patents

결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도 Download PDF

Info

Publication number
KR102702675B1
KR102702675B1 KR1020237010151A KR20237010151A KR102702675B1 KR 102702675 B1 KR102702675 B1 KR 102702675B1 KR 1020237010151 A KR1020237010151 A KR 1020237010151A KR 20237010151 A KR20237010151 A KR 20237010151A KR 102702675 B1 KR102702675 B1 KR 102702675B1
Authority
KR
South Korea
Prior art keywords
antibody
ctla
dose
administered
nivolumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237010151A
Other languages
English (en)
Korean (ko)
Other versions
KR20230047498A (ko
Inventor
마이클 액셀슨
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59078186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102702675(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Priority to KR1020247029228A priority Critical patent/KR20240134249A/ko
Publication of KR20230047498A publication Critical patent/KR20230047498A/ko
Application granted granted Critical
Publication of KR102702675B1 publication Critical patent/KR102702675B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237010151A 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도 Active KR102702675B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247029228A KR20240134249A (ko) 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662345662P 2016-06-03 2016-06-03
US62/345,662 2016-06-03
PCT/US2017/035822 WO2017210637A1 (en) 2016-06-03 2017-06-02 Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
KR1020187038115A KR102515509B1 (ko) 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187038115A Division KR102515509B1 (ko) 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247029228A Division KR20240134249A (ko) 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도

Publications (2)

Publication Number Publication Date
KR20230047498A KR20230047498A (ko) 2023-04-07
KR102702675B1 true KR102702675B1 (ko) 2024-09-05

Family

ID=59078186

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237010151A Active KR102702675B1 (ko) 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
KR1020187038115A Active KR102515509B1 (ko) 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
KR1020247029228A Pending KR20240134249A (ko) 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020187038115A Active KR102515509B1 (ko) 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
KR1020247029228A Pending KR20240134249A (ko) 2016-06-03 2017-06-02 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도

Country Status (7)

Country Link
US (3) US11332529B2 (enExample)
EP (2) EP3464373B1 (enExample)
JP (3) JP2019517512A (enExample)
KR (3) KR102702675B1 (enExample)
CN (1) CN109476754A (enExample)
ES (1) ES2897964T3 (enExample)
WO (1) WO2017210637A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
KR20170080697A (ko) 2014-11-13 2017-07-10 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
SG10201912035YA (en) * 2015-04-17 2020-02-27 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
AU2016294440B2 (en) 2015-07-13 2022-10-13 Cytomx Therapeutics, Inc Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof
PL3334763T3 (pl) 2015-08-11 2024-12-02 WuXi Biologics Ireland Limited Nowe przeciwciała anty-pd-1
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
WO2017210637A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
CN111770936A (zh) * 2018-01-12 2020-10-13 百时美施贵宝公司 抗il-8抗体和抗pd-1抗体联合治疗用于治疗癌症
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
BR112020015915A8 (pt) * 2018-02-13 2023-01-31 Merck Sharp & Dohme Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
WO2020033283A1 (en) * 2018-08-09 2020-02-13 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc
AU2019337547A1 (en) * 2018-09-13 2021-03-18 Merck Sharp & Dohme Llc Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
JP2022527177A (ja) * 2019-03-28 2022-05-31 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍を処置する方法
GB201912107D0 (en) * 2019-08-22 2019-10-09 Amazentis Sa Combination
CN110656179A (zh) * 2019-10-29 2020-01-07 至本医疗科技（上海）有限公司 免疫敏感性预测的生物标志组成物及用途、试剂盒设备存储介质
CN115569193B (zh) * 2021-10-09 2024-04-02 施慧达药业集团(吉林)有限公司 戈氏梭菌芽孢联合帕博利珠单抗的应用及治疗结肠癌药物和戈氏梭菌芽孢冻干粉制备方法
EP4612182A1 (en) * 2022-10-31 2025-09-10 Agenus Inc. Methods of treating colorectal cancer using an anti-ctla4 antibody
TWI898418B (zh) * 2023-02-09 2025-09-21 安邦生技股份有限公司 用以治療大腸癌的藥學套組及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077553A1 (en) * 2014-11-13 2016-05-19 The Johns Hopkins University Checkpoint blockade and microsatellite instability

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
DK1212422T3 (da) 1999-08-24 2007-07-02 Medarex Inc Humane CTLA-4-antistoffer og anvendelserne deraf
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
EP1340819A1 (en) * 2002-02-28 2003-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsatellite markers
ATE481985T1 (de) 2002-07-03 2010-10-15 Ono Pharmaceutical Co Immunpotenzierende zusammensetzungen
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
WO2005021743A1 (ja) * 2003-08-29 2005-03-10 Tanaka, Noriaki 核酸増幅用プライマー及びこれを用いた大腸癌の検査方法
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
HRP20080053A2 (hr) 2005-07-01 2009-08-31 Medarex Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1)
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP5798919B2 (ja) 2008-08-25 2015-10-21 アンプリミューン、インコーポレーテッドＡｍｐｌｉｍｍｕｎｅ， Ｉｎｃ． Ｐｄ−１アンタゴニストの組成物および使用方法
CA3120172A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
HUE037159T2 (hu) 2009-11-24 2018-08-28 Medimmune Ltd Targetált kötõdõ ágensek B7-H1 ellen
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
MX360254B (es) 2011-03-10 2018-10-26 Pfizer Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
EP3403672A1 (en) 2011-04-20 2018-11-21 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
FI20115709A0 (fi) 2011-07-01 2011-07-01 Helsingin Yliopisto Menetelmä perinnöllisten syöpien diagnosointiin
MX349096B (es) 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
ES2845609T3 (es) 2013-05-02 2021-07-27 Anaptysbio Inc Anticuerpos dirigidos contra muerte programada-1 (PD-1)
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
SI3081576T1 (sl) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
AU2015210886A1 (en) * 2014-01-29 2016-09-01 Caris Mpi, Inc. Molecular profiling of immune modulators
SG11201707383PA (en) 2015-03-13 2017-10-30 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
CN106714836A (zh) 2015-06-05 2017-05-24 H·李·莫菲特癌症中心研究有限公司 Gm‑csf/cd40l疫苗和检查点抑制剂联合治疗
WO2017210637A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
WO2018183408A1 (en) * 2017-03-31 2018-10-04 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077553A1 (en) * 2014-11-13 2016-05-19 The Johns Hopkins University Checkpoint blockade and microsatellite instability

Also Published As

Publication number Publication date
JP2023002567A (ja) 2023-01-10
EP3464373A1 (en) 2019-04-10
EP3988570A1 (en) 2022-04-27
KR20230047498A (ko) 2023-04-07
KR20190015406A (ko) 2019-02-13
US20220356254A1 (en) 2022-11-10
JP7721494B2 (ja) 2025-08-12
CN109476754A (zh) 2019-03-15
ES2897964T3 (es) 2022-03-03
US20250026831A1 (en) 2025-01-23
WO2017210637A1 (en) 2017-12-07
JP2025143276A (ja) 2025-10-01
EP3464373B1 (en) 2021-10-27
US20190153100A1 (en) 2019-05-23
US11332529B2 (en) 2022-05-17
JP2019517512A (ja) 2019-06-24
KR20240134249A (ko) 2024-09-06
KR102515509B1 (ko) 2023-03-28

Similar Documents

Publication Publication Date Title
JP7721494B2 (ja) 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用
KR102870759B1 (ko) 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
CN108969763B (zh) 通过破坏pd-1/pd-l1信号传输的免疫治疗
KR102710067B1 (ko) 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도
CN113230398B (zh) 用于治疗非小细胞肺癌的抗-b7-h1和抗-ctla-4抗体
EP3572430A2 (en) Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
CN111094982A (zh) 用于治疗和诊断癌症的tim-3拮抗剂
WO2019143607A1 (en) Methods of treating cancer with antibodies against tim3
CN111148996A (zh) 用于检查点抑制剂的预测性外周血生物标志物
JP2022547550A (ja) Ｐｄ－１軸阻害剤及び抗ペリオスチン抗体の使用により癌を処置する方法。
CN117980336A (zh) 抗tnfr2抗体及其用途
CN117603360A (zh) 用于治疗癌症的多特异性抗体
KR20220066334A (ko) Lag-3 길항제 요법에 대한 정량적 공간 프로파일링
CN111973739A (zh) 抗pd-l1单克隆抗体治疗癌症的用途
KR20240099362A (ko) 혈액암에 대한 lag-3 길항제 요법
EA050488B1 (ru) Композиции и способы для лечения рака легкого на поздней стадии

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601